Moreover, various breast cancer mouse models have consistently indicated that pharmacological inhibition of IL-1 signalling, by Anakinra or Canakinumab also reduced bone turnover resulting in higher % bone volume/tissue volume (BV/TV) in mouse tibias and reduced activity of both osteoclasts and osteoblasts compared with mice in control groups [4], [5], [7], [8], [9]. This evidence concerns the gene IL1B and breast carcinoma.